提升抗肿瘤疫苗的效率的重要途径是：诱导产生特异而且高活力的效应性T细胞；同时削弱Treg等免疫抑制因素。申请人前期实验结果表明综合运用免疫佐剂CpG ODN/MPL，同时联合 survivin蛋白疫苗能够明显减缓黑色素瘤荷瘤小鼠的肿瘤生长速度，但是其抗肿瘤机制尚不明确。本项目在前期工作基础上拟从肺癌模型小鼠出发，考察免疫佐剂CpG ODN/MPL促进特定亚型DC成熟以及增强幼稚T细胞分化为高效的效应性T细胞的能力；同时用适量的化疗药物（环磷酰胺）以减弱肿瘤微环境中的免疫抑制因素，力图大幅提高survivin抗肿瘤疫苗在实验动物与临床中的效果。本项目将研究疫苗与化学药物联合使用的协同效应，并探索相关的分子作用机制，是抗肿瘤转化医学研究的前沿课题。本实验室前期的预实验结果表明相关研究内容与方案切实可行，项目的实施有望提供抗肿瘤治疗的新途径与新策略。

Elevated cancer vaccine efficacy was induced by specific and activated effector T cells, and weak immunosuppressive factors such as Treg. We demonstrated that CpG ODN/MPL adjuvanted survivin protein cancer vaccine was capable of significantly inhibiting tumor growth of melanoma tumor-bearing mice previously, however, the mechnism was still unclear. This project plans to investigate the capability of the immuno-adjuvant CpG ODN/MPL for promoting different subtypes of DCs maturation, and further promoting naive T cell differentiation to effect T cells in a lung carcinoma mouse model. Chemical drug cyclophosphamide is also administrated to to eliminate the tumor microenvironment immunosuppressive factors, which brought the vaccine’s maximized effect in pre-clinical and clinical trials. This project aimed at synergies of immunotherapy and chemotherapy, and further explore the related mechanism. Which is a forefront issue of anti-neoplastic translational medicine research. Previous results of preliminary experiments in our laboratory showed that the methods related is practical, implementation of the project is expected to provide new ways of anti-tumor therapy and strategies.